Intuitive Surgical (ISRG)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$468.52-2.82%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · ISRG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 29.4% |
| Our one-year growth estimate | diamond | 13.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 16.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 10 industry peers · Company calendar date is not available
ISRG — director transition
Dated 2026-11-02
Director — Aaron Martin: The filing discloses the appointment of a new independent director to fill a vacancy created by a board size increase, which is a routine governance action.
Why it matters: More da Vinci 5 placements can grow the installed base using the new system. Q3 placements rose to 315 from 240 a year earlier.
Supportive ifA later quarter reports more da Vinci 5 placements than the 315 placed in Q3 2026.
Worry ifA later quarter reports fewer da Vinci 5 placements than the 240 placed in Q3 2025.
Why it matters: Management raised its margin range from Q2. Tariffs could still weigh on margins if new duties take effect.
Watch forFull-year 2026 non-GAAP gross margin lands within the latest 68.7% to 69.3% range.
Also watch forFull-year 2026 non-GAAP gross margin falls below 68.7%, or management lowers the range.
Why it matters: Ion procedures drive demand for its tools and can expand use of the system. Q3 Ion procedure growth was about 31%.
Supportive ifA later quarter reports Ion procedure growth above 30% year over year.
Worry ifA later quarter reports Ion procedure growth below 20% year over year.
Why it matters: Procedure growth drives use of da Vinci tools and systems. Q3 growth was 14%, and management kept its full-year guide near 14% to 15%.
Supportive ifFull-year 2026 da Vinci procedure growth lands at 14% or higher, within management's 14% to 15% guide.
Worry ifFull-year da Vinci procedure growth falls below 14%, or management cuts the 2026 guide below 14%.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$136 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $304 loss on $10,000 · 3.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,400 loss on $10,000 · 44.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Court approval would close a major legal matter. The agreement also includes injunctive relief, and the court may reject it.
Watch forThe court gives preliminary and final approval to the $450 million settlement. Its terms have no material change.
Also watch forThe court denies approval, or the settlement terms change in a way that raises the payment or adds new relief.